ABCB5 and recessive dystrophic epidermolysis bullosa: Taken together, in addition to hUCB-MSCs and BM-MSCs, human dermal ABCB5+ MSCs or MSC-derived extracellular vesicles also can be alternative therapeutic candidates in the field of cell therapy for RDEB.